

Supplementary Tables

Supplementary Table 1: Treatment details of the cancer patients receiving a homologous BNT162b2 booster after double-dose BNT162b1 vaccination

Treatment types the enrolled homologous boosted cancer patients (N=149) were receiving at time of first dose and when the homologous BNT162b2 booster was administered..

Therapy at first dose		Therapy at third dose	
B-cell depletion	25 (16.8%)	B-cell depletion	14 (56.0%)
		Other hematological cancer treatments	4 (16.0%)
		No current treatment	7 (28.0%)
Chemotherapy	33 (22.1%)	Chemotherapy	9 (27.3%)
		Immunotherapy	1 (3.0%)
		Targeted/Hormone therapy	12 (36.4%)
		No current treatment	10 (30.3%)
		Unknown	1 (3.0%)
Other hematological cancer treatments	11 (7.4%)	B-cell depletion	1 (9.1%)
		Other hematological cancer treatments	10 (90.9%)
Immunotherapy + chemotherapy	4 (2.7%)	Immunotherapy + chemotherapy	3 (75.0%)
		Immunotherapy	1 (25.0%)
Immunotherapy	10 (6.7%)	Immunotherapy	9 (90.0%)
		No current treatment	1 (10.0%)
Targeted/Hormone therapy	66 (44.3%)	Chemotherapy	3 (4.5%)
		Immunotherapy	3 (4.5%)
		B-cell depletion	1 (1.5%)
		Targeted/Hormone therapy	57 (86.4%)
		No current treatment	2 (3.0%)

Supplementary Table 2: Treatment details of the cancer patients receiving a homologous BNT162b2 booster after double-dose ChAdOx1 vaccination

Treatment types the enrolled homologous boosted cancer patients (N=149) were receiving at time of first dose and when the homologous BNT162b2 booster was administered.

Therapy at first dose		Therapy at third dose	
B-cell depletion	19 (13.8%)	B-cell depletion	7 (36.8)
		Other hematological cancer treatments	1 (5.3%)
		No current treatment	5 (26.3%)
		Unknown	6 (31.6%)
Chemotherapy	48 (34.8%)	Chemotherapy	8 (16.7%)
		Immunotherapy	1 (2.1%)
		Immunotherapy + chemotherapy	1 (2.1%)
		Targeted/Hormone therapy	2 (4.2%)
		No current treatment	7 (14.6%)
		Unknown	29 (60.4%)
Other hematological cancer treatments	14 (10.1%)	Other hematological cancer treatments	12 (85.7%)
		No current treatment	2 (14.3%)
Immunotherapy + chemotherapy	4 (2.9%)	Chemotherapy	1 (25.0%)
		Immunotherapy	1 (25.0%)
		Targeted/Hormone therapy	1 (25.0%)
		Unknown	1 (25.0%)
Immunotherapy	21 (15.2%)	Chemotherapy	1 (4.8%)
		Immunotherapy	4 (19.0%)
		Unknown	16 (76.2%)
Targeted/Hormone therapy	32 (23.2%)	Targeted/Hormone therapy	22 (68.8%)
		Unknown	10 (31.2%)